Sublytic terminal complement attack on myotubes decreases the expression of mrnas encoding muscle-specific proteins

Journal of Neurochemistry

Volumn 68, Issue 4, 1997, Pages 1581-1589

  Lang, Thomas J ^a,b   Badea, Tudor C ^a   Wade, Robert ^a   Shin, Moon L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

C5b 9; Complement; mRNA stability; Muscle specific genes; Slow twitch isoform of troponin I transcription

Indexed keywords

MESSENGER RNA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; COMPLEMENT ACTIVATION; CYTOLYSIS; CYTOTOXICITY; EFFECTOR CELL; GENE EXPRESSION REGULATION; INFLAMMATORY CELL; MOUSE; MUSCLE DISEASE; MYASTHENIA GRAVIS; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM;

ANIMALIA;

EID: 0030950505     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68041581.x     Document Type: Article

References (59)

1. Asher O., Fuchs S., Zuk D., Rapaport D., and Buonanno A. (1992) Changes in the expression of mRNAs for myogenic factors and other muscle-specific proteins in experimental autoimmune myasthenia gravis. FEBS Lett. 299, 15-18.
2. Ashizawa T. and Appel S. H. (1985) Immunopathologic events at the endplate in myasthenia gravis. Springer Semin. Immunopathol. 8, 177-196.
3. Bengal E., Ransone L., Scharfmann R., Dwarki V. J., Tapscott S. J., Weintraub H., and Verma I. M. (1992) Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell 68, 507-519.
4. Bhakdi S. and Tranum-Jensen J. (1987) Damage to mammalian cells by proteins that form transmembrane pores. Rev. Physiol. Biochem. Pharmacol. 107, 148-223.
5. Biesecker G. and Gomez C. M. (1989) Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142, 2654-2659.
6. Blau H. M., Pavlath G. K., Hardeman E. C., Chiu C. P., Silberstein L., Webster S. G., Miller S. C., and Webster C. (1985) Plasticity of the differentiated state. Science 230, 58-66.
7. Brasier A. R. and Ron D. (1992) Luciferase reporter gene assay in mammalian cells. Methods Enzymol. 216, 386-397.
8. Carney D. F., Lang T. J., and Shin M. L. (1990) Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J. Immunol. 145, 623-629.
9. Chen C. Y. and Shyu A. B. (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20, 465-470.
10. Cooper N. R. and Nemerow G. R. (1983) Complement, viruses, and virus-infected cells. Springer Semin. Immunopathol. 6, 327-347.
11. Corin S. J., Juhasz O., Zhu L., Conley P., Kedes L., and Wade R. (1994) Structure and expression of the human slow twitch skeletal muscle troponin I gene. J. Biol. Chem. 269, 10651-10659.
12. Corin S. J., Levitt L. K., Joya J. E., Hardeman E., and Wade R. (1995) Delineation of a slow-twitch-myofiber-specific transcriptional element by using in vivo somatic gene transfer. Proc. Natl. Acad. Sci. USA 92, 6185-6189.
13. Drachman D. B., Angus C. W., Adams R. N., Michelson J. D., and Hoffman G. J. (1978) Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 298, 1116-1122.
14. Fisher S. N., Kim Y.-U., and Shin M. L. (1994) Tyrosine kinase activation by Newcastle disease virus is required for TNF-α gene induction in astrocytes. J. Immunol. 153, 3210-3217.
15. Frank M. (1995) Complement system, in Samter's Immunologic Diseases (Frank M. M., Austen K. F., Claman H. N., and Unanue E. R., eds), pp. 331-352. Little and Brown, Boston.
16. Fumagalli G., Engel A. G., and Lindstrom J. M. (1982) Ultrastructural aspects of acetylcholine receptor turnover at the normal end-plate and in autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 41, 567-579.
17. Gomez C. M. and Richman D. P. (1985) Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J. Immunol. 135, 234-241.
18. Gunning P., Hardeman E., Wade R., Ponte P., Bains W., Blau H. M., and Kedes L. (1987) Differential patterns of transcript accumulation during human myogenesis. Mol. Cell. Biol. 7, 4100-4114.
19. Halperin J. A., Taratuska A., and Nicholson-Weller A. (1993) Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J. Clin. Invest. 91, 1974-1978.
20. Hansch G. M., Seitz M., and Betz M. (1987) Effect of late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int. Arch. Allergy Appl. Immunol. 82, 317-320.
21. Hong K., Kinoshita T., Miyazaki W., Izawa T., and Inoue K. (1979) An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade. J. Immunol. 122, 2418-2423.
22. Hong K., Kinoshita T., and Inoue K. (1981) Simple methods for preparing EAC1,4b,2a,3b and EAC4b,3b with human or guinea pig complement components using an anticomplementary agent, K-76 monocarboxylic acid. J. Immunol. 127, 109-114.
23. Huang L. Y., Tholanikunnel B. G., Vakalopoulou E., and Malbon C. C. (1993) The M(r) 35,000 beta-adrenergic receptor mRNA-binding protein induced by agonists requires both an AUUUA pentamer and U-rich domains for RNA recognition. J. Biol. Chem. 268, 25769-25775.
24. Joiner K. A., Brown E. J., and Frank M. M. (1984) Complement and bacteria: chemistry and biology in host defense. Annu. Rev. Immunol. 2, 461-491.
25. Koishi K., Zhang M., McLennan I. S., and Harris A. J. (1995) MyoD protein accumulates in satellite cells and is neurally regulated in regenerating myotubes and skeletal muscle fibers. Dev. Dyn. 202, 244-254.
26. Kues W. A., Brenner H. R., Sakmann B., and Witzemann V. (1995) Local neurotrophic repression of gene transcripts encoding fetal AChRs at rat neuromuscular synapses. J. Cell Biol. 130, 949-957.
27. Lassar A. B., Davis R. L., Wright W. E., Kadesch T., Murre C., Voronova A., Baltimore D., and Weintraub H. (1991) Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305-315.
28. Lennon V. A., Seybold M. E., Lindstrom J. M., Cochrane C., and Ulevitch R. (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147, 973-983.
29. Lindstrom J. M., Einarson B. L., Lennon V. A., and Seybold M. E. (1976a) Pathological mechanisms in experimental autoimmune myasthenia gravis. J. Exp. Med. 144, 726-738.
30. Lindstrom J. M., Engel A. G., Seybold M. E., Lennon V. A., and Lambert H. A. (1976b) Pathological mechanisms in experimental autoimmune myasthenia gravis. J. Exp. Med. 144, 739-753.
31. Ludolph D. C. and Konieczny S. F. (1995) Transcription factor families: muscling in on the myogenic program. FASEB J. 9, 1595-1604.
32. Luo Z., Fuentes M. E., and Taylor P. (1994) Regulation of acetylcholinesterase mRNA stability by calcium during differentiation from myoblasts to myotubes. J. Biol. Chem. 269, 27216-27223.
33. Ma P. C., Rould M. A., Weintraub H., and Pabo C. O. (1994) Crystal structure of MyoD bHLH domain-DNA complex: perspectives on DNA recognition and implications for transcriptional activation. Cell 77, 451-459.
34. Medford R. M., Nguyen H. T., and Nadal-Ginard B. (1983) Transcriptional and cell cycle-mediated regulation of myosin heavy chain gene expression during muscle cell differentiation. J. Biol. Chem. 258, 11063-11073.
35. Minty A. and Kedes L. (1986) Upstream regions of the human cardiac actin gene that modulate its transcription in muscle cells: presence of an evolutionarily conserved repeated motif. Mol. Cell. Biol. 6, 2125-2136.
36. Morgan B. P. and Campbell A. K. (1985) The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by charges in intracellular free calcium. Biochem. J. 23, 205-208.
37. Niculescu F., Rus H., Shin S., Lang T., and Shin M. L. (1993) Generation of diacylglycerol and ceramide during homologous complement activation. J. Immunol. 150, 214-224.
38. Niculescu F., Rus H., and Shin M. L. (1994) Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J. Biol. Chem. 269, 4417-4423.
39. Niculescu F., Rus H., and Shin M. L. (1996) Assembly of terminal complement complexes induces activation of both Erk1 and Jnk1 in B lymphocytes. (Abstr.) Mol. Immunol. 33 (Suppl. 1), 82.
40. Olson E. N., Perry M., and Schultz R. A. (1995) Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Dev. Biol. 172, 2-14.
41. Rantanen J., Hurme T., Lukka R., Heino J., and Kalimo H. (1995) Satellite cell proliferation and the expression of myogenin and desmin in regenerating skeletal muscle: evidence for two different populations of satellite cells. Lab. Invest. 72, 341-347.
42. Rus H., Niculescu F., and Shin M. L. (1996) Sublytical complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156, 4892-4900.
43. Sahashi K., Engel A. G., Lambert E. H., and Howard F. M. Jr. (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39, 160-172.
44. Sambrook J., Fritsch E. F., and Maniatis T. (1989) Molecular Cloning, pp. 7.3-7.84. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
45. Seeger W., Suttorp N., Hellwig A., and Bhakdi S. (1986) Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J. Immunol. 137, 1286-1293.
46. Shaw G. and Kamen R. (1986) A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667.
47. Shin M. L., Rus H. G., and Niculescu F. I. (1996) Membrane attack by complement: assembly and biology of terminal complement complexes, in Biomembranes, Vol. 4 (Lee A. K., ed), pp. 123-149. JAI Press, Greenwich, Connecticut.
48. Shirazi Y., McMorris F. A., and Shin M. L. (1989) Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte X C6 glioma cell hybrids. J. Immunol. 142, 4385-4391.
49. Shirazi Y., Rus H. G., Macklin W. B., and Shin M. L. (1993) Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes. J. Immunol. 150, 4581-4590.
50. Shyu A. B., Greenberg M. E., and Belasco J. G. (1989) The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev. 3, 60-72.
51. Thompson J. F., Hayes L. S., and Lloyd D. B. (1991) Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene 103, 171-177.
52. Wade R., Eddy R., Shows T. B., and Kedes L. (1990a) cDNA sequence, tissue-specific expression, and chromosomal mapping of the human slow-twitch skeletal muscle isoform of troponin I. Genomics 7, 346-357.
53. Wade R., Sutherland C., Gahlmann R., Kedes L., Hardeman E., and Gunning P. (1990b) Regulation of contractile protein gene family mRNA pool sizes during myogenesis. Dev. Biol. 142, 270-282.
54. Weintraub H. (1993) The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75, 1241-1244.
55. Weiss I. M. and Liebhaber S. A. (1994) Erythroid cell-specific determinants of alpha-globin mRNA stability. Mol. Cell. Biol. 14, 8123-8132.
56. Weiss I. M. and Liebhaber S. A. (1995) Erythroid cell-specific mRNA stability elements in the alpha 2-globin 3′ nontranslated region. Mol. Cell. Biol. 15, 2457-2465.
57. 2+-initiated activation of cellular protein kinases. J. Biol. Chem. 262, 13674-13681.
58. Yaffe D. and Saxel O. (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270, 725-727.
59. Zhu Y. Y., Schwartz R. J., and Crow M. T. (1991) Phorbol esters selectively downregulate contractile protein gene expression in terminally differentiated myotubes through transcriptional repression and message destabilization. J. Cell Biol. 115, 745-754.